ITP
Iron Triangle Partners Portfolio holdings
AUM
$632M
This Quarter Return
+6.33%
1 Year Return
+26.53%
3 Year Return
+134.07%
5 Year Return
+312.1%
10 Year Return
–
AUM
$693M
AUM Growth
+$693M
(+24%)
Cap. Flow
+$113M
Cap. Flow
% of AUM
16.33%
Top 10 Holdings %
Top 10 Hldgs %
57.68%
Holding
38
New
12
Increased
10
Reduced
5
Closed
11
Top Buys
| 1 |
AbbVie
ABBV
|
$51M |
| 2 |
UnitedHealth
UNH
|
$37.8M |
| 3 |
Evolent Health
EVH
|
$32.5M |
| 4 |
Sanofi
SNY
|
$28.8M |
| 5 |
DexCom
DXCM
|
$25.6M |
Top Sells
| 1 |
Universal Health Services
UHS
|
$42.3M |
| 2 |
Repligen
RGEN
|
$30.1M |
| 3 |
Boston Scientific
BSX
|
$27.8M |
| 4 |
United Therapeutics
UTHR
|
$19.9M |
| 5 |
Cigna
CI
|
$19.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Brookdale Senior Living
BKD
$1.83B
| $7.97M | 1.15% |
+2,700,000
| New | +$7.97M |
|
27
Stereotaxis
STXS
$247M
| $3.74M | 0.54% |
1,832,577
+161,468
| +10% | +$329K |
|
28
Amylyx Pharmaceuticals
AMLX
$877M
| – | – |
-240,240
| Closed | -$8.88M |
|
|
29
Boston Scientific
BSX
$159B
| – | – |
-600,000
| Closed | -$27.8M |
|
|
30
Cigna
CI
$80.2B
| – | – |
-60,000
| Closed | -$19.9M |
|
31
Karyopharm Therapeutics
KPTI
$61.4M
| – | – |
-128,452
| Closed | -$6.55M |
|
32
Neurocrine Biosciences
NBIX
$13.5B
| – | – |
-100,089
| Closed | -$12M |
|
|
33
Repligen
RGEN
$6.54B
| – | – |
-178,000
| Closed | -$30.1M |
|
34
Syndax Pharmaceuticals
SNDX
$1.39B
| – | – |
-370,294
| Closed | -$9.42M |
|
|
35
Universal Health Services
UHS
$11.6B
| – | – |
-300,000
| Closed | -$42.3M |
|
|
36
United Therapeutics
UTHR
$17.7B
| – | – |
-71,576
| Closed | -$19.9M |
|
|
NARI
37
DELISTED
Inari Medical, Inc. Common Stock
NARI
| – | – |
-190,000
| Closed | -$12.1M |
|
|
RXDX
38
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-75,000
| Closed | -$8.25M |
|